Combination of Lanreotide Autogel and Temozolomide in Patients with Progressive Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NET) - A Pilot-Study

被引：0
|
作者：
Raderer, M. [1 ]
Hoersch, D. [2 ]
Lahner, H. [3 ]
Rinke, A. [4 ]
Denecke, T. [5 ]
Koch, A. [5 ]
Raspel, A. [6 ]
Hoffmanns, P. [6 ]
Pavel, M. [5 ]
机构：
[1] AKH, Vienna, Austria
[2] Zentralklin, Bad Berka, Germany
[3] Univ Klin, Essen, Germany
[4] Univ Klin, Marburg, Germany
[5] Charite, Berlin, Germany
[6] IPSEN, Ettlingen, Germany
来源：
NEUROENDOCRINOLOGY | 2016年 / 103卷
关键词：
GEP-NET; Lanreotide; Temozolomide;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K6
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [1] Impact of Early Surgery on Prognosis in Advanced Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NET)
    Hammer, P.
    Lipp, R.
    Thalhammer, M.
    Mischinger, H. J.
    Kornprat, P.
    Puntschart, A.
    Uranues, S.
    Haybaeck, J.
    Krejs, G.
    Kump, P.
    NEUROENDOCRINOLOGY, 2016, 103 : 98 - 98
  • [2] Management of gastro-entero-pancreatic neuroendocrine tumours (GEP NET): an introduction
    Van Hootegem, Ph.
    Borbath, I.
    Verslype, C.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2009, 72 (01) : 27 - 28
  • [3] Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET)
    Xue, Mingzhan
    Shafie, Alaa
    Qaiser, Talha
    Rajpoot, Nasir M.
    Kaltsas, Gregory
    James, Sean
    Gopalakrishnan, Kishore
    Fisk, Adrian
    Dimitriadis, Georgios K.
    Grammatopoulos, Dimitris K.
    Rabbani, Naila
    Thornalley, Paul J.
    Weickert, Martin O.
    ONCOTARGET, 2017, 8 (44) : 76961 - 76973
  • [4] Impact of VEGF and VEGFR Polymorphisms on Neuroendocrine Tumors of the Gastro-Entero-Pancreatic System (GEP-NET) Outcome
    Berardi, R.
    Pagliaretta, S.
    Rinaldi, S.
    Morgese, F.
    Partelli, S.
    Caramanti, M.
    Onofri, A.
    Polenta, V.
    Pasquini, S.
    Falconi, M.
    Cascinu, S.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 105 - 105
  • [5] Conditional Survival (CS) Analysis of Liver Resection (LR) for Gastro-Entero-Pancreatic Neuroendocrine Tumor (GEP-NET)
    Coppa, J.
    Bongini, M.
    Scotti, M.
    Flores, M.
    Bianchi, Z.
    Monteleone, M.
    Milione, M.
    Mazzaferro, V
    NEUROENDOCRINOLOGY, 2017, 105 : 262 - 262
  • [6] CHARACTERISTICS OF LONG-ACTING SOMATOSTATIN (SSA) USE IN GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE (GEP-NET) TUMORS IN THE NETHERLANDS
    Bezemer, I. D.
    Penning, F. J. A.
    Brulais, S.
    Verduyn, C. S. C.
    Herings, R. M. C.
    VALUE IN HEALTH, 2012, 15 (07) : A435 - A435
  • [7] Prognostic Influence of Inflammation-based Risk Scores in Neuroendocrine Tumors of the Gastro-entero-Pancreatic System (GEP-NET)
    Witte, H.
    Ziehm, M.
    Gebauer, J.
    Luley, K.
    Von Bubnoff, N.
    Steinestel, K.
    Bauer, A.
    Gebauer, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 154 - 154
  • [8] Combined lanreotide autogel and temozolomide therapy in progressive neuroendocrine tumours: the SONNET study
    Hoersch, D.
    Raderer, M.
    Lahner, H.
    Rinke, A.
    Denecke, T.
    Koch, A.
    Raspel, A.
    Hoffmanns, P.
    Pavel, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)
    Lamberti, Giuseppe
    Prinzi, Natalie
    Bongiovanni, Alberto
    Torniai, Mariangela
    Andrini, Elisa
    de Biase, Dario
    Malvi, Deborah
    Mosca, Mirta
    Berardi, Rossana
    Ibrahim, Toni
    Pusceddu, Sara
    Campana, Davide
    DIAGNOSTICS, 2023, 13 (09)
  • [10] Validation of Lysyl Oxidase-Like 2 (LOXL2) as Prognostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NET) Using an Independent Cohort
    Barriuso, J.
    Benavent, M.
    Lamarca, A.
    Bernal, E.
    Guerra-Pastrian, L.
    Heredia, V
    Miguel, M.
    Garcia-Calderon, C. B.
    Alvarez-Escola, C.
    Castell, J.
    Custodio, A.
    Burgos, E.
    Feliu, J.
    Carbonero R, Garcia
    Mendiola, M.
    NEUROENDOCRINOLOGY, 2016, 103 : 44 - 44
12345